Lv11
90 积分 2025-08-18 加入
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
28天前
已完结
600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ERBB2-Negative Advanced Breast Cancer
1个月前
已完结
Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
1个月前
已完结
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma
2个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
2个月前
已完结
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
2个月前
已完结
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
2个月前
已完结
皖公网安备34019202002308
